Compare VRA & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | ALGS |
|---|---|---|
| Founded | 1982 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 43.0M |
| IPO Year | 2010 | 2020 |
| Metric | VRA | ALGS |
|---|---|---|
| Price | $2.73 | $7.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | ★ 145.7K | 33.8K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $416,097,000.00 | $2,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.61 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.39 | $3.76 |
| 52 Week High | $3.41 | $13.69 |
| Indicator | VRA | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 48.76 |
| Support Level | $1.91 | $6.92 |
| Resistance Level | $2.84 | $7.50 |
| Average True Range (ATR) | 0.15 | 0.54 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 56.52 | 73.11 |
Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.